CORT (Corcept Therapeutics) Price-to-Operating-Cash-Flow : 47.08 (As of Jul. 01, 2025)

View and export this data going back to 2004. Start your Free Trial

What is Corcept Therapeutics Price-to-Operating-Cash-Flow?

As of today (2025-07-01), Corcept Therapeutics's share price is $73.40. Corcept Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $1.56. Hence, Corcept Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is 47.08.

The historical rank and industry rank for Corcept Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

CORT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.92 Med: 21.67 Max: 177.86
Current: 47.08

During the past 13 years, Corcept Therapeutics's highest Price-to-Operating-Cash-Flow Ratio was 177.86. The lowest was 8.92. And the median was 21.67.

CORT's Price-to-Operating-Cash-Flow is ranked worse than
71.62% of 303 companies
in the Biotechnology industry
Industry Median: 24.72 vs CORT: 47.08

Corcept Therapeutics's Cash Flow from Operations per share for the three months ended in Mar. 2025 was $0.04. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $1.56.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Corcept Therapeutics was 37.80% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 9.40% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 5.20% per year.

During the past 13 years, Corcept Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 215.80% per year. The lowest was -4.40% per year. And the median was 7.85% per year.

Corcept Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Corcept Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics Price-to-Operating-Cash-Flow Chart

Corcept Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

21.37

14.85

19.57

28.57

28.88

Corcept Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															22.27	29.14	35.93	28.88	73.26

Competitive Comparison of Corcept Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Corcept Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corcept Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Corcept Therapeutics Price-to-Operating-Cash-Flow Calculation

Corcept Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	73.40	/	1.559
	=	47.08

Corcept Therapeutics's Share Price of today is $73.40.
Corcept Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.56.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Corcept Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Corcept Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (NAS:CORT) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

0I3Q:UK HTD:Germany HTD:Germany

Address

101 Redwood Shores Parkway, Redwood City, CA, USA, 94065

Website

https://www.corcept.com

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Executives

Gary Charles Robb	officer: CHIEF FINANCIAL OFFICER	C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
David L Mahoney	director	SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
William Guyer	officer: Chief Development Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Swisher Daniel N Jr	director	C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Sean Maduck	officer: See Remarks	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph K Belanoff	director, officer: CHIEF EXECUTIVE OFFICER	149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph Douglas Lyon	officer: Chief Accounting Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Hazel Hunt	officer: Chief Scientific Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Baker G Leonard Jr	director, 10 percent owner	755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005
Joshua M. Murray	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Atabak Mokari	officer: Chief Financial Officer	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Gillian Cannon	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gregg H Alton	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Kimberly Park	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Andreas Grauer	officer: Chief Medical Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025